Dr Reddys Laboratories RDY
NYSE RDY
$14.88 -0.02 (-0.17%)
As of: Nov 9, 2026 · 9:56 AM EST

Dr Reddys Laboratories (RDY) Gains from Equity Investments (2023 - 2024)

Updated

Dr Reddys Laboratories (RDY) posted Gains from Equity Investments of $1 million for FY2026 (year ended Mar 31, 2026), down 66.7% from $3 million in FY2025.

Analysis

Dr Reddys Laboratories (RDY) Gains from Equity Investments (2023 - 2024) Analysis & Trends

Since FY2018, Dr Reddys Laboratories has reported Gains from Equity Investments for 9 fiscal years.

  • Annual Gains from Equity Investments shows a five-year compound annual growth rate of -32.2% (FY2021 to FY2026).
  • The FY2026 figure stands as the lowest annual Gains from Equity Investments in data going back to FY2018.
  • Business Quant data shows RDY's Gains from Equity Investments at $3 million in FY2025 (+50.0%), $2 million in FY2024 (-60.0%), $5 million in FY2023 (-44.4%) and $9 million in FY2022 (+28.6%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,231.10 Bn 1,204.71 Bn 20.46 Bn
2 Johnson & Johnson 669.11 Bn 588.97 Bn 17.30 Bn
3 AbbVie 513.20 Bn 481.21 Bn 13.12 Bn
4 Merck 361.72 Bn 324.66 Bn 13.19 Bn
5 Novartis Ag 313.59 Bn 286.83 Bn -
6 Astrazeneca 290.36 Bn 264.25 Bn 13.26 Bn
7 Amgen 246.51 Bn 198.16 Bn 7.58 Bn
8 Gilead Sciences 206.71 Bn 181.82 Bn 6.73 Bn
9 Pfizer 165.30 Bn 112.66 Bn 12.56 Bn
10 Dr Reddys Laboratories 12.36 Bn 11.70 Bn 472.93 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 3.12 Mn
Mar 31, 2023 8.08 Mn
API Access

Dr Reddys Laboratories Gains from Equity Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-equity-investments&ticker=RDY&period=max&api_key=YOUR_API_KEY